Access cutting-edge lymphoma treatment through this clinical trial at a research site in New Orleans. Study-provided care at no cost to qualified participants.
Access lymphoma specialists in New Orleans at no cost
This study follows strict safety protocols and ethical guidelines
All study-related lymphoma treatment provided free
The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen receptor T cell (CAR-T) therapy. This study consists of 3 arms each in Phase 2 and 3. Phase 2 portion of the study will assess the two doses of selinexor (40 milligram \[mg\] or 60 mg) in combination with R-GDP, for up to 6 cycles (21-day per cycle), fol
Sponsor: Karyopharm Therapeutics Inc
Check if you qualify for this lymphoma clinical trial in New Orleans, LA
If you're searching for lymphoma treatment options in New Orleans, LA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New Orleans research site is actively enrolling participants for this clinical trial. You'll receive care from experienced lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.